目前慢性丙型肝炎(CHC)的标准疗法为聚乙二醇干扰素-α(PEG-IFN-α)联合利巴韦林,但该疗法存在一定的局限性.近年来针对HCV生活周期的小分子抗病毒药物迅速发展,给将来的治疗带来了新的希望.%The currently standardized therapy for hepatitis C virus (HCV) infection is the combination ofa pegylated interferon alfa (PEG-IFN-α) and ribavirin, howerver, the IFN-based therapy regimen is by far still the ideal choice. Recently, some small molecules antiviral compound that specifically targets the life circle of HCV made some quick developement, and may offer hope for future therapies.
展开▼
